Displaying drugs 6976 - 7000 of 8495 in total
Dezamizumab
Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
Investigational
Matched Description: … Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled …
Ebopiprant
Ebopiprant is under investigation in clinical trial NCT03369262 (Poc Study of OBE022 in Threatened Preterm Labour).
Investigational
Matched Description: … Ebopiprant is under investigation in clinical trial NCT03369262 (Poc Study of OBE022 in Threatened Preterm …
Esflurbiprofen
Esflurbiprofen is under investigation in clinical trial NCT03434197 (Safety and Efficacy of SFPP in Knee Osteoarthritis).
Investigational
Matched Description: … Esflurbiprofen is under investigation in clinical trial NCT03434197 (Safety and Efficacy of SFPP in Knee …
Rivenprost
Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).
Investigational
Matched Description: … Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for …
JTC-801 free base
An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.
Investigational
Matched Description: … An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment. …
rAAV9-rsATP7A
A recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes disease.
Investigational
Matched Description: … A recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes …
Oleandrin
Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity.
Experimental
Investigational
Matched Description: … Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity …
DDP-225
DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a...
Investigational
Matched Description: … Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the ... The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered …
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … these have met the requirements of an ideal oral drug candidate. ... excellent properties in brain penetration, selectivity, metabolic stability, and oral availability; all of …
Loprazolam
Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings. Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence...
Experimental
Matched Description: … It is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. ... It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or …
Fenbendazole
Fenbendazole is a benzimidazole that presents a wide spectrum anthelmintic effect. It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and Strongyloides. Fenbendazole is approved to be administered under veterinary to sheep, cattle, horses, fish, dogs,...
Vet approved
Matched Description: … It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms ... , the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and Strongyloides …
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
Matched Description: … It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type …
SYNB1353
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion...
Investigational
Matched Description: … SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered ... A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of …
GS030-DP
GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector. It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Investigational
Matched Description: … GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. ... It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device …
ADL5859
ADL5859 is a novel, oral compound that targets the Delta opioid receptor. Delta receptor agonists are thought to offer benefits over other approaches to the management of pain.
Investigational
Matched Description: … Delta receptor agonists are thought to offer benefits over other approaches to the management of pain …
Vatreptacog alfa
Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
Investigational
Matched Description: … Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia …
Evogliptin
Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.
Investigational
Matched Description: … Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment …
5-fluoro-2'-deoxycytidine
5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
Investigational
Matched Description: … 5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms …
Mavoglurant
Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).
Investigational
Matched Description: … Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant …
Avadomide
Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).
Investigational
Matched Description: … Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, …
Marzeptacog alfa (activated)
Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
Investigational
Matched Description: … investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of …
Elgemtumab
Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Investigational
Matched Description: … investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of …
Bisphosphocin Nu-3
Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).
Investigational
Matched Description: … investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of …
Fenpyroximate
Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).
Investigational
Matched Description: … Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid …
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of …
Displaying drugs 6976 - 7000 of 8495 in total